Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility

Both trials, designed to assess efficacy in heart‑failure patients, were stopped for futility, meaning interim analyses indicated the drug was unlikely to meet its primary endpoints. Coverage of the cancellation appeared simultaneously across five specialist outlets. Fierce Biotech framed the move as a blow to Novo’s “blockbuster hopes for its CKD program,” while firstwordpharma.com noted that the two heart‑failure studies were halted early, further eroding confidence in ziltivekimab. STAT highlighted the broader implication that the drug, intended to lower inflammation, will no longer be tested in cardiovascular settings.

Reuters linked the scrapped trials to a dimming outlook for growth beyond Novo’s core obesity franchise, and Endpoints News issued an update confirming the futility finding. Together, the reports underscore both the scientific setback and the strategic ramifications for the Danish group. The next observable steps will likely come from Novo’s own communications, including any updates to its pipeline roadmap or reallocations of research funding. Investors and analysts will watch for statements on whether the CKD program will continue unchanged or be reprioritized in light of the cardiovascular setbacks.

Regulatory filings, upcoming conference presentations, and potential initiation of alternative trials in related indications are also signals to monitor. Market reaction to the news, as reflected in share price movements and analyst coverage, will further indicate how the cancellation reshapes expectations for Novo’s growth beyond obesity.